title: Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?
abstract: OBJECTIVE
  To determine whether alpha-blockers, commonly used for the treatment of benign prostatic hyperplasia, are associated with prostate cancer risk.
  
  
  RESULTS
  Alpha-blockers have been associated with a reduced risk of prostate cancer aggressiveness in some observational studies and an increased risk in other studies. However, this relationship is complex as different alpha-blockers have divergent effects in laboratory studies and there are many confounders in daily practice such as differential screening practices.
  
  
  CONCLUSIONS
  Both benign prostatic hyperplasia and prostate cancer are common conditions in the aging male population, such that an interaction between alpha-blockers and prostate cancer risk is clinically relevant. Prospective evidence is necessary to establish a definitive link.
authors.affiliation: Department of Urology, New York University, New York, New York, USA. stacyloeb@gmail.com
authors.forename: Stacy
authors.initials: S
authors.lastname: Loeb
authors.forename: Angela
authors.initials: A
authors.lastname: Gupta
authors.forename: Lia
authors.initials: L
authors.lastname: Losonczy
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Tosoian
authors.forename: Patrick C
authors.initials: PC
authors.lastname: Walsh
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000401:mortality; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists